Research Article
BibTex RIS Cite

Seroprevalence of Toxoplasma Gondii, Rubella and Cytomegalovirus Among Pregnant Women in Our Clinic

Year 2023, Volume: 10 Issue: 1, 29 - 33, 10.04.2023
https://doi.org/10.47572/muskutd.1078037

Abstract

To determine the rate of seropositivity in toxoplasma, rubella and cytomegalovirus infections during pregnancy. 4488 pregnants who applied to outpatient polyclinics of Gynecology and Obstetrics in Muğla Sıtkı Koçman University Training and Research Hospital for pregnancy examination in the first 10 weeks of pregnancy were included in the study. Results of anti-Toxoplasma IgM and IgG, anti-Rubella IgM and IgG, anti-CMV IgM and IgG were evaluated. Seropositivity rates of anti-Toxoplasma, anti-Rubella, anti-CMV IgG and IgM were determined respectively 21.6%, 1.6%, 92.8%, 1%; 98.5%, 1.1% in the study group. Toxoplasma, Rubella and CMV seroprevalence should be evaluated during preconceptional or antenatal screening according to regional conditions.

References

  • 1. Yadav RK, Maity S, Saha S. A review on TORCH: groups of congenital infection during pregnancy. J Sci In Res. 2014;3(2):258-64.
  • 2. Newton ER. Diagnosis of perinatal TORCH infections. Clin Obstet Gynecol. 1999;42(1):59-70.
  • 3. Tamer GS, Dundar D, Caliskan E. Seroprevalence of Toxoplasma gondii, rubella and cytomegalovirus among pregnant women in western region of Turkey. Clin Invest Med. 2009;32(1):43-7.
  • 4. Abdel Fattah SA, Bhat A, Illanes S, et al. TORCH test for fetal medicine indications: only CMV is necessary in the United Kingdom. Prenat Diagn. 2005;25(11):1028-31.
  • 5. Kasap B, Öner G, Küçük M, et al. Muğla’daki gebelerin toksoplazma, rubella, sitomegalovirüs ve hepatit prevalansının değerlendirilmesi. Tepecik Eğit Araşt Hast Derg. 2017;27(1):31-6.
  • 6. Neu N, Duchon J, Zachariah P. TORCH infections. Clin Perinatol. 2015;42(1):77-103.
  • 7. Numan O, Vural F, Aka N, et al. TORCH seroprevalence among patients attending obstetric Care Clinic of Haydarpasa Training and Research Hospital affiliated to association of Istanbul northern Anatolia public hospitals. North Clin Istanb. 2015;2(3):203.
  • 8. Zeb MA, Jamal SF, Mir A, et al. Frequency of Torch Infections during Pregnancy in Peshawar. Adv Appl Sci Res. 2018;9:22-6.
  • 9. Obaid HM, Juma SA. TORCH screening test in pregnant women of Kirkuk city. Al-Mustansiriyah Jour Scie. 2017;27(5):17-25.
  • 10. Zhang N, Cui X, Wei W, et al. Quantitative detection of rubella virus cytomegalovirus and toxoplasma gondii serum antibodies during pregnancy using liaison xl. Infect Dis Diag Treat. 2019;3(133):2577-1515.
  • 11. Wang LC, Yan F, Ruan JX, et al. TORCH screening used appropriately in China?─ three years results from a teaching hospital in northwest China. BMC Pregnancy Childbirth. 2019;19(1):484.
  • 12. Çiçek AÇ, Duygu F, İnakçı İH, et al. Şanlıurfa ilinde doğurganlık çağındaki kadınlarda ELISA ile Toxoplasma gondii antikorlarının araştırılması: üç yıllık değerlendirme. J Clin Exp Invest. 2012;3(1):61-5.
  • 13. Sahu SK, Pradhan SK, Nayak LM. Seroprevalence of TORCH infection among pregnant women. Int J Community Med Public Health. 2019;6(5):2189-94.
  • 14. Chen L, Liu J, Shi L, et al. Seasonal influence on TORCH infection and analysis of multi‐positive samples with indirect immunofluorescence assay. J Clin Lab Anal. 2019;33(4):e22828.
  • 15. Wang Y, Li S, Ma N, et al. The association of ToRCH infection and congenital malformations: A prospective study in China. Eur J Obstet Gynecol Reprod Biol. 2019;240:336-40.
  • 16. Özdemir M, Taşbent FE, Terzi HA, et al. Seroprevalence of major viral pathogens during pregnancy: A multicenter study in Turkey. Adv Clin Med Microbiol. 2016;1(1):1-5.
  • 17. Çetinkaya RA, Yenilmez E. The seroprevalence of Rubella in pregnant women in Turkey: a meta-analysis research of 90988 Rubella IgM, 84398 Rubella IgG, and 522 avidity results. Turk J Obstet Gynecol. 2019;16(1):63-71.
  • 18. McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep Recomm Rep. 2013;62(4):1-34.
  • 19. Gülcen BS, Tüzüner U, Feyzioğlu B, et al. Investigating seropositivitiy of Rubella IgG among women of childbearing age in Konya province. J Turgut Ozal Med Cent. 2016;23(4):384-6.
  • 20. Aynali A, Arıdoğan BC, Tola EN, et al. Doğurganlık yaş grubundaki kadınlarda Rubella IgM ve IgG seroprevalansı. Med J SDU. 2016;7(1):10-3.
  • 21. Şentürk Ş, Kağıtcı M, Balık G, et al. Seroprevalence of rubella virus among pregnant women in Eastern Black Sea Region. Van Tıp Derg. 2016;23(3):242-5.

Kliniğimizde Takipli Gebelerin Toksoplazma Gondi, Rubella ve Sitomegalovirus Seroprevelansının İncelenmesi

Year 2023, Volume: 10 Issue: 1, 29 - 33, 10.04.2023
https://doi.org/10.47572/muskutd.1078037

Abstract

Gebelik döneminde toksoplazma, rubella ve sitomegalovirüs enfeksiyonlarında seropozitiflik oranını belirlemek. Muğla Sıtkı Koçman Üniversitesi Eğitim ve Araştırma Hastanesi Kadın Hastalıkları ve Doğum Polikliniği’ne gebeliğin ilk 10 haftası içinde gebelik muayenesi için başvuran 4488 gebe çalışmaya alındı. Anti-Toksoplazma IgM ve IgG, Anti-Rubella IgM ve IgG, Anti-CMV IgM ve IgG sonuçları değerlendirildi. Çalışma grubunda Anti-Toksoplazma, Anti-Rubella, Anti-CMV IgG ve IgM seropozitiflik oranı sırası ile %21.6, %1.6; %92.8, %1; %98.5, %1.1 olarak tespit edildi. Günlük pratiğimizde sıklıkla değerlendirilen Toksoplazma, Rubella ve CMV seroprevalansını prekonsepsiyonel veya antenatal tarama döneminde bölgesel şartlara göre değerlendirilmesi maliyet ve etkinlik açısından daha uygun bir yaklaşım olacaktır. Anti-Rubella IgG taramasının prekonsepsiyonel dönemde taranması ve seronegatif hastalara aşılama yapılması uygun bir yaklaşım gibi görünmektedir.

References

  • 1. Yadav RK, Maity S, Saha S. A review on TORCH: groups of congenital infection during pregnancy. J Sci In Res. 2014;3(2):258-64.
  • 2. Newton ER. Diagnosis of perinatal TORCH infections. Clin Obstet Gynecol. 1999;42(1):59-70.
  • 3. Tamer GS, Dundar D, Caliskan E. Seroprevalence of Toxoplasma gondii, rubella and cytomegalovirus among pregnant women in western region of Turkey. Clin Invest Med. 2009;32(1):43-7.
  • 4. Abdel Fattah SA, Bhat A, Illanes S, et al. TORCH test for fetal medicine indications: only CMV is necessary in the United Kingdom. Prenat Diagn. 2005;25(11):1028-31.
  • 5. Kasap B, Öner G, Küçük M, et al. Muğla’daki gebelerin toksoplazma, rubella, sitomegalovirüs ve hepatit prevalansının değerlendirilmesi. Tepecik Eğit Araşt Hast Derg. 2017;27(1):31-6.
  • 6. Neu N, Duchon J, Zachariah P. TORCH infections. Clin Perinatol. 2015;42(1):77-103.
  • 7. Numan O, Vural F, Aka N, et al. TORCH seroprevalence among patients attending obstetric Care Clinic of Haydarpasa Training and Research Hospital affiliated to association of Istanbul northern Anatolia public hospitals. North Clin Istanb. 2015;2(3):203.
  • 8. Zeb MA, Jamal SF, Mir A, et al. Frequency of Torch Infections during Pregnancy in Peshawar. Adv Appl Sci Res. 2018;9:22-6.
  • 9. Obaid HM, Juma SA. TORCH screening test in pregnant women of Kirkuk city. Al-Mustansiriyah Jour Scie. 2017;27(5):17-25.
  • 10. Zhang N, Cui X, Wei W, et al. Quantitative detection of rubella virus cytomegalovirus and toxoplasma gondii serum antibodies during pregnancy using liaison xl. Infect Dis Diag Treat. 2019;3(133):2577-1515.
  • 11. Wang LC, Yan F, Ruan JX, et al. TORCH screening used appropriately in China?─ three years results from a teaching hospital in northwest China. BMC Pregnancy Childbirth. 2019;19(1):484.
  • 12. Çiçek AÇ, Duygu F, İnakçı İH, et al. Şanlıurfa ilinde doğurganlık çağındaki kadınlarda ELISA ile Toxoplasma gondii antikorlarının araştırılması: üç yıllık değerlendirme. J Clin Exp Invest. 2012;3(1):61-5.
  • 13. Sahu SK, Pradhan SK, Nayak LM. Seroprevalence of TORCH infection among pregnant women. Int J Community Med Public Health. 2019;6(5):2189-94.
  • 14. Chen L, Liu J, Shi L, et al. Seasonal influence on TORCH infection and analysis of multi‐positive samples with indirect immunofluorescence assay. J Clin Lab Anal. 2019;33(4):e22828.
  • 15. Wang Y, Li S, Ma N, et al. The association of ToRCH infection and congenital malformations: A prospective study in China. Eur J Obstet Gynecol Reprod Biol. 2019;240:336-40.
  • 16. Özdemir M, Taşbent FE, Terzi HA, et al. Seroprevalence of major viral pathogens during pregnancy: A multicenter study in Turkey. Adv Clin Med Microbiol. 2016;1(1):1-5.
  • 17. Çetinkaya RA, Yenilmez E. The seroprevalence of Rubella in pregnant women in Turkey: a meta-analysis research of 90988 Rubella IgM, 84398 Rubella IgG, and 522 avidity results. Turk J Obstet Gynecol. 2019;16(1):63-71.
  • 18. McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep Recomm Rep. 2013;62(4):1-34.
  • 19. Gülcen BS, Tüzüner U, Feyzioğlu B, et al. Investigating seropositivitiy of Rubella IgG among women of childbearing age in Konya province. J Turgut Ozal Med Cent. 2016;23(4):384-6.
  • 20. Aynali A, Arıdoğan BC, Tola EN, et al. Doğurganlık yaş grubundaki kadınlarda Rubella IgM ve IgG seroprevalansı. Med J SDU. 2016;7(1):10-3.
  • 21. Şentürk Ş, Kağıtcı M, Balık G, et al. Seroprevalence of rubella virus among pregnant women in Eastern Black Sea Region. Van Tıp Derg. 2016;23(3):242-5.
There are 21 citations in total.

Details

Primary Language English
Subjects Surgery
Journal Section Original Article
Authors

Mehmet Ferdi Kıncı 0000-0002-6798-4281

Ercan Saruhan 0000-0001-6416-1442

Ezgi Karakaş Paskal 0000-0002-9714-3686

Burak Ekrem Çitil 0000-0003-1043-1763

Burak Sezgin 0000-0003-2938-5816

Publication Date April 10, 2023
Submission Date February 23, 2022
Published in Issue Year 2023 Volume: 10 Issue: 1

Cite

APA Kıncı, M. F., Saruhan, E., Karakaş Paskal, E., Çitil, B. E., et al. (2023). Seroprevalence of Toxoplasma Gondii, Rubella and Cytomegalovirus Among Pregnant Women in Our Clinic. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi, 10(1), 29-33. https://doi.org/10.47572/muskutd.1078037
AMA Kıncı MF, Saruhan E, Karakaş Paskal E, Çitil BE, Sezgin B. Seroprevalence of Toxoplasma Gondii, Rubella and Cytomegalovirus Among Pregnant Women in Our Clinic. MMJ. April 2023;10(1):29-33. doi:10.47572/muskutd.1078037
Chicago Kıncı, Mehmet Ferdi, Ercan Saruhan, Ezgi Karakaş Paskal, Burak Ekrem Çitil, and Burak Sezgin. “Seroprevalence of Toxoplasma Gondii, Rubella and Cytomegalovirus Among Pregnant Women in Our Clinic”. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi 10, no. 1 (April 2023): 29-33. https://doi.org/10.47572/muskutd.1078037.
EndNote Kıncı MF, Saruhan E, Karakaş Paskal E, Çitil BE, Sezgin B (April 1, 2023) Seroprevalence of Toxoplasma Gondii, Rubella and Cytomegalovirus Among Pregnant Women in Our Clinic. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi 10 1 29–33.
IEEE M. F. Kıncı, E. Saruhan, E. Karakaş Paskal, B. E. Çitil, and B. Sezgin, “Seroprevalence of Toxoplasma Gondii, Rubella and Cytomegalovirus Among Pregnant Women in Our Clinic”, MMJ, vol. 10, no. 1, pp. 29–33, 2023, doi: 10.47572/muskutd.1078037.
ISNAD Kıncı, Mehmet Ferdi et al. “Seroprevalence of Toxoplasma Gondii, Rubella and Cytomegalovirus Among Pregnant Women in Our Clinic”. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi 10/1 (April 2023), 29-33. https://doi.org/10.47572/muskutd.1078037.
JAMA Kıncı MF, Saruhan E, Karakaş Paskal E, Çitil BE, Sezgin B. Seroprevalence of Toxoplasma Gondii, Rubella and Cytomegalovirus Among Pregnant Women in Our Clinic. MMJ. 2023;10:29–33.
MLA Kıncı, Mehmet Ferdi et al. “Seroprevalence of Toxoplasma Gondii, Rubella and Cytomegalovirus Among Pregnant Women in Our Clinic”. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi, vol. 10, no. 1, 2023, pp. 29-33, doi:10.47572/muskutd.1078037.
Vancouver Kıncı MF, Saruhan E, Karakaş Paskal E, Çitil BE, Sezgin B. Seroprevalence of Toxoplasma Gondii, Rubella and Cytomegalovirus Among Pregnant Women in Our Clinic. MMJ. 2023;10(1):29-33.